Nelfinavir

Contraindicated

Nelfinavir Colchicine Colcrys Explained Increased colchicine exposure and an increased risk of fatal toxicity Details Nelfinavir Simvastatin Flolipid Explained An increased risk of myopathy or rhabdomyolysis Details Nelfinavir Alfuzosin UroXatral Increased alfuzosin exposure and an increased risk of QT interval prolongation Details Nelfinavir Dihydroergotamine Injection DHE-45® Injection Increased dihydroergotamine exposure and an increased risk of ergotism (nausea, vomiting, vasospastic ischemia) Details Nelfinavir Dihydroergotamine Nasal Spray Migranal Increased dihydroergotamine exposure and an increased risk of ergotism (nausea, vomiting, vasospastic ischemia) Details Nelfinavir Finerenone Kerendia Increased finerenone exposure and an increased risk of finerenone-related adverse effects Details Nelfinavir Ivabradine Corlanor Increased ivabradine exposure, an increased risk of ivabradine-related adverse effects and an increased risk of QT prolongation Details Nelfinavir Ketoconazole Topical Extina® Foam Increased ketoconazole exposure, an increased nelfinavir exposure and an increased risk of QT interval prolongation Details Nelfinavir Lovastatin Altocor® Increased lovastatin exposure and an increased risk of lovastatin-related adverse effects, such as, risk of myopathy or rhabdomyol... Details Nelfinavir Lurasidone Latuda Increased lurasidone exposure Details Nelfinavir Methylergonovine Methergine Increased methylergonovine exposure and an increased risk of ergotism (nausea, vomiting, vasospastic ischemia) Details Nelfinavir Midazolam Nasal Spray Nayzilam Increased midazolam exposure and an increase risk of prolonged sedation or respiratory depression Details Nelfinavir Midazolam Injection Nayzilam Increased midazolam exposure and an increase risk of prolonged sedation or respiratory depression Details Nelfinavir Naloxegol Movantik Increased naloxegol exposure and an increased risk of naloxegol-related adverse effects Details Nelfinavir Nimodipine Nimotop Increased serum nimodipine concentrations Details

Major

Nelfinavir Acetaminophen And Codeine Capital® & Codeine Explained Increased codeine and morphine exposure Details Nelfinavir Abametapir Explained Increased exposure of CYP3A4 substrate Details Nelfinavir Omeprazole Gastrobim Explained Increased omeprazole exposure, altered nelfinavir exposure and reduced efficacy of nelfinavir Details Nelfinavir Amitriptyline Elavil Explained Increased risk of QT interval prolongation Details Nelfinavir Sertraline Explained An increased risk of QT interval prolongation Details Nelfinavir Buprenorphine Belbuca Explained An increased risk of QT interval prolongation, increased buprenorphine exposure and an increased risk of buprenorphine-related adv... Details Nelfinavir Relugolix Orgovyx Explained Increased relugolix exposure and an increased risk of QT interval prolongation Details Nelfinavir Acalabrutinib Calquence Increased acalabrutinib exposure Details Nelfinavir Ado-Trastuzumab Emtansine Injection KADCYLA Increased exposure of cytotoxic component DM1 (maytansine derivative) and risk of toxicity Details Nelfinavir Amisulpride Injection Barhemsys Increased risk of serious ventricular arrhythmias such as torsades de pointes Details Nelfinavir Apixaban Eliquis Explained Increased apixaban exposure and an increased risk of bleeding Details Nelfinavir Arsenic Trioxide Trisenox Increased risk of QT-interval prolongation and torsade de pointes Details Nelfinavir Aripiprazole Injection Abilify Increased ARIPiprazole exposure and an increased risk of QT interval prolongation Details Nelfinavir Arsenic Trioxide Injection Trisenox Increased risk of QT-interval prolongation and torsade de pointes Details Nelfinavir Asciminib Scemblix Increased asciminib exposure and an increased risk of asciminib-related adverse effects Details Nelfinavir Asenapine Transdermal Patch Secuado Increased risk of QT interval prolongation Details Nelfinavir Atogepant Qulipta Increased atogepant exposure Details Nelfinavir Avapritinib Ayvakit Increased avapritinib exposure and increased incidence and severity of adverse reactions Details Nelfinavir Azithromycin AzaSite Increased azithromycin exposure, an increased risk of adverse effects (diarrhea, ototoxicity, hepatotoxicity) and an increased ris... Details Nelfinavir Atorvastatin Atorvaliq Increased atorvastatin exposure and an increased risk of myopathy and rhabdomyolysis Details Nelfinavir Cariprazine Vraylar Explained Increased exposure to cariprazine and its active metabolite, didesmethylcariprazine Details Nelfinavir Amlodipine Amvaz® Increased amLODIPine exposure and an increased risk of hypotension and edema Details Nelfinavir Anagrelide Agrylin Increased risk of QT interval prolongation Details Nelfinavir Avanafil Stendra Decreased avanafil clearance and increased avanafil plasma concentration Details Nelfinavir Axitinib Inlyta Increased axitinib plasma concentrations Details